key: cord-1013635-h8dlzw2g authors: Cevik, M.; Tate, M.; Lloyd, O.; Maraolo, A. E.; Schafers, J.; Ho, A. title: SARS-CoV-2 viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and meta-analysis date: 2020-07-28 journal: nan DOI: 10.1101/2020.07.25.20162107 sha: 60bb08853f1fe78c0959e51b4683fb044b138c93 doc_id: 1013635 cord_uid: h8dlzw2g Background Viral load kinetics and the duration of viral shedding are important determinants for disease transmission. We aim i) to characterise viral load dynamics, duration of viral RNA, and viable virus shedding of SARS-CoV-2 in various body fluids and ii) to compare SARS-CoV-2 viral dynamics with SARS-CoV-1 and MERS-CoV. Methods: Medline, EMBASE, Europe PMC, preprint servers and grey literature were searched to retrieve all articles reporting viral dynamics and duration of SARS-CoV-2, SARS-CoV-1 and MERS-CoV shedding. We excluded case reports and case series with < 5 patients, or studies that did not report shedding duration from symptom onset. PROSPERO registration: CRD42020181914. Findings: Seventy-nine studies on SARS-CoV-2, 8 on SARS-CoV-1, and 11 on MERS-CoV were included. Mean SARS-CoV-2 RNA shedding duration in upper respiratory tract, lower respiratory tract, stool and serum were 17.0, 14.6, 17.2 and 16.6 days, respectively. Maximum duration of SARS-CoV-2 RNA shedding reported in URT, LRT, stool and serum was 83, 59, 35 and 60 days, respectively. Pooled mean duration of SARS-CoV-2 RNA shedding was positively associated with age (p=0.002), but not gender (p = 0.277). No study to date has detected live virus beyond day nine of illness despite persistently high viral loads. SARS-CoV-2 viral load in the upper respiratory tract appears to peak in the first week of illness, while SARS-CoV-1 and MERS-CoV peak later. Conclusion: Although SARS-CoV-2 RNA shedding in respiratory and stool can be prolonged, duration of viable virus is relatively short-lived. Thus, detection of viral RNA cannot be used to infer infectiousness. High SARS-CoV-2 titres are detectable in the first week of illness with an early peak observed at symptom onset to day 5 of illness. This review underscores the importance of early case finding and isolation, as well as public education on the spectrum of illness. However, given potential delays in the isolation of patients, effective containment of SARS-CoV-2 may be challenging even with an early detection and isolation strategy. Funding: No funding was received. Viral load kinetics and the duration of viral shedding are important determinants for disease 56 transmission. They determine the duration of infectiousness which is a critical parameter to inform 57 effective control measures and disease modelling. While a number of studies have evaluated 58 (slope: +0.304; 95% CI, +0.115 to +0.493; p = 0.002 Fig 6) , but not gender (p = 0.277, 135 Supplementary Fig 3) . When adjusted for the proportion of male subjects in a multivariable 136 analysis, mean age was positively associated with the mean duration of viral shedding in URT 137 specimens (p = 0.003). There was a positive but non-significant association between mean age 138 and duration of shedding in stool (p=0.37) (Supplementary Fig 4) . 139 The majority of studies evaluating SARS-CoV-2 viral load in serial URT samples demonstrated 141 peak viral loads within the first week of symptom onset. 2, 4, 8, [16] [17] [18] [19] [20] [21] [22] [23] [24] The highest viral loads were 142 reported either soon after or at the time of symptom onset 2, 8, 16, 23, 24 or at day 3-5 of illness 4,18,20,22 143 followed by a consistent decline. 144 Five studies that evaluated viral load dynamics in LRT samples observed a peak viral load in the 145 second week of illness. 4, 18, 20, 23, 25 In contrast, the dynamics of SARS-CoV-2 shedding in stool is 146 more erratic, with highest viral loads reported on day 7, 18 2-3 weeks, 24, 25 and up to 5-6 weeks 147 after symptom onset. 23 While several studies reported significantly higher viral titres in stool 148 compared to respiratory samples, 8 In total, 20 studies evaluated duration of viral RNA shedding based on disease severity. The 153 majority (n=13) reported longer duration of viral shedding in patients with severe illness than 154 those with non-severe illness, 18, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] while five studies reported similar shedding durations 155 according to disease severity in URT samples 17, 19, [37] [38] [39] and one study in stool samples. 40 Only 156 one study reported shorter viral shedding in moderate to severe illness compared to mild to 157 moderate illness. 41 Six studies have performed comparative analysis based on severity of 158 illness; 18, 25, 27, 28, 38, 39 the majority (n=5) demonstrated significantly longer duration of shedding 159 among the severe illness group compared to the non-severe patients and only one study 160 observed no difference. 39 (Table 2) . 161 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 28, 2020. . https://doi.org/10.1101/2020.07. 25.20162107 doi: medRxiv preprint Other factors associated with prolonged shedding 162 All but one study 42 (n=10) that examined the impact of age on SARS-CoV-2 shedding identified 163 an association between older age and prolonged viral RNA shedding. 25, 26, 28, 33, [37] [38] [39] [43] [44] [45] Three 164 studies identified age as an independent risk factor for delayed viral clearance. 25, 26, 38 Male sex 165 was also associated with prolonged shedding, 25, 38, 46 and the association remained significant 166 even when patients were stratified based on illness severity. 25, 38 Corticosteroid treatment was 167 associated with delayed viral clearance in four studies, 33, 38, 47, 48 and one study that recruited 120 168 critically ill patients, found no difference between corticosteroid and control groups. 49 169 In a phase 2 open-label study evaluating interferon beta-1b, lopinavir-ritonavir, and ribavirin a 170 shorter duration of viral shedding was seen with combination treatment compared to the 171 control. 50 None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) 172 independently improved viral RNA clearance. 28, 51 In a retrospective study of 284 patients, 173 lopinavir/ritonavir use was associated with delayed viral clearance even after adjusting for 174 confounders. 28 175 Twelve studies reported on viral load dynamics and/or duration of viral shedding among patients 177 with asymptomatic SARS-CoV-2 infection (Table 3) ; two demonstrated lower viral loads among 178 asymptomatic patients compared to symptomatic patients, 8, 52 while four studies found similar 179 initial viral loads. 13, 14, 53, 54 However, Chau et al reported significantly lower viral load in 180 asymptomatic patients during the follow up compared to symptomatic patients. 53 Faster viral 181 clearance was observed in asymptomatic individuals in five out of six studies. 13, 28, 53, 55, 56 The 182 exception Yongchen et al., found longer shedding duration among asymptomatic cases, but the 183 difference was not significant. 36 184 We identified 11 studies that attempted to isolate live virus. All eight studies that attempted virus 186 isolation in respiratory samples successfully cultured viable virus within the first week of illness, 187 9, 17, 20, 54, [57] [58] [59] [60] No live virus was isolated from any respiratory samples taken after day 8 of symptoms 188 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 28, 2020. . in three studies, 20, 57, 58 or beyond day 9 in two studies 17,54 despite persistently high viral RNA loads. 189 One study demonstrated the highest probability of positive culture on day 3 of symptoms. 57 Arons 190 et al. cultured viable virus 6 days before typical symptom onset, however onset of symptom was 191 unclear. 54 192 The success of viral isolation correlated with viral load quantified by RT-PCR. No successful viral 193 culture was obtained from samples with a viral load below 10 6 copies/ml, 20 Ct values >24, 57 194 or >34, 54, 58 with culture positivity declining with increasing Ct values. 58 Several other studies 195 cultured live virus from RT-PCR positive specimens; however, they did not correlate these results 196 with viral load titres. 9,59,60 197 Only one study reported the duration of viable virus shedding in respiratory samples; the median 198 time to clearance from URT and LRT samples was 3.5 and 6 days, respectively. 20 Arons et al. 199 cultured viable virus in one out of three asymptomatic cases from the respiratory tract. 54 All attempts to isolate virus from RT-PCR-positive stool specimens collected >6weeks after 215 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2020. . disease onset failed. 61 The isolation probability for stool samples was approximately 5 to 10 216 times lower compared to respiratory specimens. 64 We identified 11 studies on MERS-CoV. Three studies (324 subjects) reporting MERS-CoV 218 shedding in URT and four studies (93 subjects) in LRT were included in the quantitative analysis. 219 The mean shedding duration was 15.3 days (95% CI, 11.6 -19.0) and 16.6 days (95% CI, 14.8 -220 18.4), respectively ( Supplementary Figures 1 and 2 ). Only one study reported duration of viral 221 shedding in serum with a median of 14 days and max of 38 days. 71 In a small study, mortality rates 222 were higher in patients with viraemia. 72 In URT and LRT specimens, prolonged shedding was 223 associated with illness severity 73, 74 and survival 75 with the shortest duration observed in 224 asymptomatic patients. 73 Peak viral loads were observed between days 7 to 10 and higher viral 225 loads was observed among patients with severe illness and fatal outcome. 71, 73, 74, 76, 77 Differences 226 in viral loads between survivors and fatal cases was more pronounced in the second week of 227 illness (P< .0006). 77 The proportion of successful viable culture was 6% in respiratory samples 228 with a viral load values below 10 7 copies/ml. 78 229 All but 11 studies (6 cohort studies, 2 cross-sectional studies, and 1 RCT on SARS-CoV-2 and 2 231 cohort studies on MERS-CoV) were case series, the majority of which recruited non-consecutive 232 patients and therefore prone to possible selection bias. (Supplementary Table 1 RNA loads, thus emphasising that the infectious period cannot be inferred from the duration of 240 viral RNA detection. This finding is supported by several studies demonstrating a relationship 241 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2020. . course. 79, 80 No secondary cases were identified beyond 5 days after the symptom onset. 81 Although modelling studies estimated potential viral load peak before symptom onset, we did not 253 identify any study that confirms pre-symptomatic viral load peak. 16 254 Emerging evidence suggests a correlation between virus persistence and disease severity and 255 outcome. 18, 25, [27] [28] [29] 38 This is consistent with the viral load dynamics of influenza, MERS-CoV, and 256 SARS-CoV-1 whereby severity of illness was also associated with prolonged viral 257 shedding. 73 Although viral loads at the start of infection appear to be comparable between asymptomatic and 268 symptomatic patients infected with SARS-CoV-2, most studies demonstrate faster viral clearance 269 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2020. . This is the first study that has comprehensively examined and compared SARS-CoV-2, SARS-283 CoV-1 and MERS-CoV viral dynamics and performed a meta-analysis of viral shedding duration. 284 Our study has limitations. First, some patients in the included studies received a range of 285 treatments, including steroids and antivirals, which may have modified the shedding dynamics. 286 Second, most of the included studies are case series, which are particularly vulnerable to 287 selection bias. Third, our meta-analysis identified substantial study heterogeneity, likely due to 288 differences in study population, follow up and management approaches. Further, shedding 289 duration is reported as median ± IQR for most studies, but meta-analysis necessitates 290 conversion to mean ± SD. 6 The validity of this conversion is based on the assumption that 291 duration of viral shedding is normally distributed, which may not apply to some studies. 292 In conclusion, although SARS-CoV-2 RNA shedding can be prolonged in respiratory and stool 293 samples, the duration of viable virus is short-lived, with culture success associated with viral load 294 levels. No study has reported live SARS-CoV-2 beyond day nine. Most studies detected the 295 SARS-CoV-2 viral load peak within the first week of illness. These findings highlight that isolation 296 practices should be commenced with the start of first symptoms including mild and atypical 297 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2020. . https://doi.org/10.1101/2020.07.25.20162107 doi: medRxiv preprint symptoms that precede more typical COVID-19 symptoms. This systematic review underscores 298 the importance of early case finding and isolation, as well as public education on the spectrum of 299 illness. However, given potential delays in the isolation of patients, effective containment of 300 SARS-CoV-2 may be challenging even with an early detection and isolation strategy. 87 All authors have nothing to disclose. 314 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2020. . 12 Guangzhou, China Hospital Case series 10 6.6 6 (60) URT, rectal swab Yan et al. 39 Hubei is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2020. . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 28, 2020. . https://doi.org/10.1101/2020.07.25.20162107 doi: medRxiv preprint Note: the overall effect is plotted as a black square. Test for heterogeneity: Q-value = 4076,08, df(Q) = 42, p < 0.001, I 2 = 99%. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 28, 2020. . https://doi.org/10.1101/2020.07.25.20162107 doi: medRxiv preprint Note: the overall effect is plotted as a black square. Test for heterogeneity: Q-value = 77,6, df(Q) = 1, p < 0.001, I 2 = 99%. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 28, 2020. . https://doi.org/10.1101/2020.07.25.20162107 doi: medRxiv preprint Note: the plot was built upon 41 studies (no data on mean age from the study of Qian et al. 98 ). A random-effects model was used. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 28, 2020. . COVID-19 pandemic-a focused review for clinicians SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients Virological assessment of hospitalized patients with COVID-2019 Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19 The Joanna Briggs Institute Critical Appraisal tools for use in JBI systematic reviews-checklist for case series Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features Early Release -Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19 Shedding of infectious SARS-CoV-2 in symptomatic neonates, children and adolescents Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha Epidemiological and Clinical Characteristics of Children with Coronavirus Disease Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo' Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China Temporal dynamics in viral shedding and transmissibility of COVID-19 Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Virological assessment of hospitalized patients with COVID-2019 Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study Virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China COVID-19 in a designated infectious diseases hospital outside Clinical progression of patients with COVID-19 in Shanghai Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients Viral dynamics in mild and severe cases of COVID-19 Viral Shedding Time in Covid-19 Inpatients Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19 Factors associated with prolonged viral RNA shedding in patients with COVID-19 Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection Prolonged presence of SARS-CoV-2 viral RNA in faecal samples Clinical research and factors associated with prolonged duration of viral shedding in patients with COVID-19 The duration of viral shedding of discharged patients with severe COVID-19 Natural History of Asymptomatic SARS-CoV-2 Infection Duration of Viral Clearance in IDF Soldiers with Mild COVID-19. medRxiv Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients Delayed clearance of SARS-CoV2 in male compared to female patients: High ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Corticosteroid Treatment in Critically Ill Patients with COVID-19: A Retrospective Cohort Study Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an openlabel, randomised, phase 2 trial arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study Viral dynamics in asymptomatic patients with COVID-19 The natural history and transmission potential of asymptomatic SARS-CoV-2 infection Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease Predicting infectious SARS-CoV-2 from diagnostic samples Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards Severe Acute Respiratory Syndrome Coronavirus 2 Shedding by Travelers Consistent Detection of 2019 Novel Coronavirus in Saliva Long-term SARS coronavirus excretion from patient cohort Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19 SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus Laboratory diagnosis of SARS Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome Severe acute respiratory syndrome in dialysis patients Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study Response to Emergence of Middle East Respiratory Syndrome Coronavirus Viral load kinetics of MERS coronavirus infection Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study Predictors of mortality in Middle East respiratory syndrome (MERS) Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection Infectious middle east respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. The Lancet Infectious Diseases Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection Detection of SARS-CoV-2 in Different Types of Clinical Specimens Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community SARS-CoV-2 detection, viral load and infectivity over the course of an infection Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan Impact of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Inflammatory Responses and Viral Clearance in COVID-19 Patients: A Multicenter Retrospective Cohort Study Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset Clinical Characteristics of Patients Hospitalized with Coronavirus Disease Duration of SARS-CoV-2 viral shedding during COVID-19 infection No SARS-CoV-2 in expressed prostatic secretion of patients with coronavirus disease 2019: a descriptive multicentre study in China Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients Detection of 2019 novel coronavirus in semen and testicular biopsy specimen of COVID-19 patients Clinical and epidemiological features of COVID-19 family clusters in Beijing Analysis of factors affected the SARS-CoV-2 viral shedding time of COVID-19 patients in Anhui, China: a retrospective study The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China Clinical characteristics and fecal-oral transmission potential of patients with COVID-19. medRxiv Epidemiological and clinical features of imported and local patients with coronavirus disease 2019 (COVID-19 Conjunctival polymerase chain reaction-tests of 2019 novel coronavirus in patients in Shenyang Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase Epidemiology and predictors of survival of MERS-CoV infections in Riyadh region Descriptive Epidemiology, Clinical Characteristics and Outcomes for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infected Patients in AlAin -Abu Dhabi Emirate Replicative virus shedding in the respiratory tract of patients with Middle East respiratory syndrome coronavirus infection 54 NR No difference in viral load NS Chau et al. 53 NR Initial viral load similar. Asymptomatic patients had significantly lower viral load during the follow up compared to symptomatic patients and faster viral clearance in asymptomatic, compared to symptomatic individuals 0.027Chen et al. 28 6 (3.5-10) Significantly shorter duration of viral shedding among asymptomatic cases (median 6 days, IQR 3.5-10), with increasing shedding duration associated with increasing illness severity <0.0001Han et al. 8 NR Symptomatic children had higher initial RNA load in nasopharyngeal swab specimens than asymptomatic children (9.01 vs. 6.32 log10 copies/mL; p = 0.048). Hu et al. 55 6 (2-12) Asymptomatic patients had shorter duration of viral shedding compared to pre-symptomatic patients (median duration of SARS-CoV-2 positivity was 6.0 (2.0 -12.0) compared to 12.0 (12.0 -14.0)) NR Lavezzo et al. 14 Le et al. 59 Sakurai et al. 43 9 (6-11) NR N/A Yang et al. 56 Significantly shorter duration of viral shedding from nasopharynx swabs was observed among asymptomatic compared to symptomatic patients Yongchen et al. 36 18 (5-28) Longer shedding duration among asymptomatic cases (median 18 days, range 5-28), compared to non-severe (10 days, range 2-21) and severe (14 days, range 9-33) cases NS Zhang et al. 13 9.63 Initial viral load similar, viral clearance occurred earlier in the asymptomatic (9.6 days) and symptomatic individuals (9.7 days, compared to pre-symptomatic group (13.6 days)Zhou et al. 52